Acer Therapeutics Inc represents a commitment to developing innovative therapeutics to address unmet medical needs. The company's corporate philosophy centers around providing effective treatment options for patients who may have limited or no approved therapies available. Acer aims to prioritize patient health and well-being through rigorous research, clinical development, and regulatory processes. By leveraging its expertise and resources, Acer strives to make a positive impact on the lives of individuals with rare diseases and other serious medical conditions. Through its dedication to scientific innovation and patient-centric approach, Acer Therapeutics Inc aims to improve global healthcare outcomes.

Acer Therapeutics Inc is primarily present in the United States.

Acer Therapeutics Inc, a leading biopharmaceutical company, has achieved several significant milestones. The company successfully received U.S. Food and Drug Administration (FDA) Fast Track designation for its flagship product, Edsivo™, for the treatment of vEDS, a life-threatening genetic disorder. Additionally, Acer Therapeutics Inc completed a successful Phase 2 clinical trial for Edsivo™, demonstrating its potential in treating vEDS patients. The company also obtained Orphan Drug designation from the FDA for ACER-001, a fully taste-masked and immediate-release formulation of sodium phenylbutyrate, intended to treat patients with urea cycle disorders. Acer Therapeutics Inc's milestones highlight their commitment to innovation and addressing unmet medical needs in rare diseases.

Acer Therapeutics Inc. is a pharmaceutical company with a rich history and background. Founded in 2017, Acer is dedicated to developing and commercializing innovative therapies for rare and life-threatening diseases. The company focuses on creating treatments for serious conditions, including vascular Ehlers-Danlos syndrome (vEDS) and maple syrup urine disease (MSUD), among others. With a strong commitment to patient care, Acer Therapeutics strives to make a positive impact on the lives of individuals suffering from these rare diseases. Its research and development efforts underscore the company's mission to improve treatment options and enhance the quality of life for affected patients.

The main competitors of Acer Therapeutics Inc in the market include companies such as BioMarin Pharmaceutical Inc, Strongbridge Biopharma plc, and Ultragenyx Pharmaceutical Inc.

Acer Therapeutics Inc is primarily active in the biotechnology industry.

The business model of Acer Therapeutics Inc revolves around the development and commercialization of innovative therapies for rare and life-threatening diseases. As a pharmaceutical company, Acer focuses on identifying and advancing potential treatments to address unmet medical needs. By conducting rigorous research and clinical trials, Acer aims to bring novel therapies to patients who may have limited treatment options. This includes leveraging partnerships, collaborations, and strategic acquisitions to expand their pipeline and accelerate the development process. Ultimately, Acer Therapeutics Inc strives to improve the quality of life for individuals affected by rare diseases through the delivery of effective and accessible treatment solutions.

Acer Therapeutics KGV ir 3,48.

Acer Therapeutics KUV ir 0,21.

AlleAktien kvalitātes vērtējums Acer Therapeutics ir 5/10.

gaidāmā Acer Therapeutics apgrozījums ir 49,40 milj. USD.

gaidāmā Acer Therapeutics peļņa ir 2,99 milj. USD.

Acer Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of therapies for rare diseases. It is headquartered in Cambridge, Massachusetts and was founded in 2017. The business model of Acer Therapeutics is based on the identification, development, and marketing of drugs for the treatment of rare diseases. The company focuses on diseases that currently have no effective treatment options and utilizes innovative technologies based on advanced scientific knowledge. Acer Therapeutics' portfolio includes various product candidates in different stages of development. One of the key products is the drug Edsivo, developed for the treatment of Vascular Ehlers-Danlos Syndrome (vEDS). vEDS is a rare connective tissue disorder that can lead to life-threatening vascular complications and has had no specific therapies available until now. Edsivo is currently in Phase III of clinical development and has been granted "Breakthrough Therapy" status by the US Food and Drug Administration (FDA), which allows for accelerated approval. Another product of Acer Therapeutics is ACER-001, developed for the treatment of Urea Cycle Disorders, a group of genetic disorders that result in a deficiency of enzymes necessary for ammonia metabolism in the body. ACER-001 is currently in Phase II of clinical development and has been granted "Orphan Drug" status by the FDA, which provides special advantages in market approval. Additional product candidates of Acer Therapeutics are ACER-801, being developed for the treatment of Phenylketonuria, and ACER-2820, which could be suitable for the treatment of Niemann-Pick Disease Type C. Both products are still in preclinical development. The business model of Acer Therapeutics is to successfully develop and bring these products to market, utilizing a combination of internal development activities and strategic partnerships with other companies and research institutions. Acer Therapeutics has already entered into several collaborations with renowned partners to accelerate and optimize the development of its product candidates. Acer Therapeutics finances its activities through a combination of equity financing and debt financing. Since its inception, the company has conducted multiple successful financing rounds, raising several million US dollars in total. In summary, Acer Therapeutics' business model is focused on developing and bringing innovative therapies for rare diseases to market. The company relies on innovative technologies, strategic partnerships, and sustainable financing. With its portfolio of promising product candidates, Acer Therapeutics has the potential to significantly impact the rare disease market and improve the lives of millions of people.

Acer Therapeutics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Acer Therapeutics vai uzņēmums nedod dividendes.

Acer Therapeutics ISIN ir US00444P1084.

Acer Therapeutics WKN ir A2DYQV.

Acer Therapeutics simbols ir ACER.

Pēdējo 12 mēnešu laikā Acer Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Acer Therapeutics plāno maksāt dividendes 0 USD apmērā.

Acer Therapeutics pašreizējā dividendu rentabilitāte ir .

Acer Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Acer Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Acer Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Acer Therapeutics apmērā 0 USD, kas tika izmaksāta 26.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 26.09.2024..

Pēdējās dividendes izmaksa notika 26.09.2024..

Gadā 2023, Acer Therapeutics izmaksāja 0 USD dividendes.

Acer Therapeutics dividendes tiek izmaksātas USD.